CStone Pharmaceuticals (CStone) announced that updated clinical results for its core asset, CS2009—a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody—have been selected for two Rapid Oral presentations at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for 23–26 October 2026 in Madrid.

The presentations will cover: • Advanced Non-Small Cell Lung Cancer (NSCLC): Phase II data will be presented on 25 October (Presentation 2616RO) in the metastatic NSCLC category. • Metastatic Colorectal Cancer (mCRC): Phase I/II safety and efficacy results will be shared on 24 October (Presentation 1953RO) under investigational immunotherapy.

Abstracts released by ESMO reflect data cut-offs as of April 2026, while more recent results are slated for disclosure at the congress. Acceptance in the Rapid Oral track signals scientific interest in CS2009’s multi-pathway mechanism, which simultaneously targets PD-1, VEGF, and CTLA-4.

Corporate context: • Founded in 2015, Hong Kong-listed CStone (HKEX: 02616) focuses on oncology, immunology and inflammation. • The company has launched four innovative drugs and obtained 21 new drug approvals across nine indications since inception. • Its pipeline comprises 16 assets, including antibody-drug conjugates, multispecific antibodies, immunotherapies and precision medicines.

Regulatory note: CStone emphasises that successful development and commercialisation of CS2009 are not assured. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.